Loading…
Innate Pharma S.A. is projected to rise to $1.81 by 2027, a +1% move from its current price of $1.79. IPHA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.74 | $1.79 | $1.85 | +0.02% |
| Jul 14 | $1.72 | $1.79 | $1.87 | +0.03% |
| Jul 15 | $1.70 | $1.79 | $1.89 | +0.05% |
| Jul 16 | $1.69 | $1.79 | $1.90 | +0.06% |
| Jul 17 | $1.68 | $1.79 | $1.92 | +0.08% |
| Jul 18 | $1.67 | $1.79 | $1.93 | +0.10% |
| Jul 19 | $1.66 | $1.79 | $1.94 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.66 | $1.79 | $1.94 | +0.11% |
| Week 2 | $1.61 | $1.80 | $2.01 | +0.23% |
| Week 3 | $1.57 | $1.80 | $2.06 | +0.34% |
| Week 4 | $1.54 | $1.80 | $2.11 | +0.45% |
| Week 5 | $1.51 | $1.80 | $2.15 | +0.57% |
| Week 6 | $1.49 | $1.80 | $2.19 | +0.68% |
| Week 7 | $1.47 | $1.81 | $2.22 | +0.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The portfolio includes Lacutamab (IPH4102), an anti-KIR3DL2 antibody in Phase II for cutaneous T-cell and peripheral T-cell lymphoma, IPH4502, a topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4, and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.
The company also develops several other candidates across immunotherapy pathways and has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Innate Pharma S.A. (IPHA) operates in the Healthcare sector. Its current price is $1.81, and the market capitalization is $169.96M, with a rank of 3,706 by market cap. The near-term outlook is reflected in the 2026 forecast, which shows an average price of $1.81 with 0% ROI and a neutral sentiment.
A major floor 34.7% below — a decisive break under it would weaken the trend.
The nearest floor, 4.6% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 25.5% above — clearing it would confirm fresh momentum.
Key IPHA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IPHA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.84 | Sell | $1.82 | Sell |
| MA 10 | $1.82 | Sell | $1.82 | Sell |
| MA 20 | $1.81 | Sell | $1.81 | Sell |
| MA 50 | $1.75 | Buy | $1.75 | Buy |
| MA 100 | $1.62 | Buy | $1.71 | Buy |
| MA 200 | $1.75 | Buy | $1.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.37 | Neutral |
| Stoch RSI (14) | 2.47 | Buy |
| CCI (20) | -40.99 | Neutral |
| Williams %R (14) | -97.27 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -5.13 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 2.73 | Buy |
| TRIX (15) | 0.20 | Buy |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 43.93 | Neutral |
| Momentum (10) | 0.00 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 1.82 | Sell |
| ADX (14) | 7.31 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is neutral, with RSI14 at 50. The stock trades around key moving averages: SMA50 is $1.67 and SMA200 is $1.76. Near-term support is at $1.32 and resistance at $2.25. Over the last 30 days, the price has ranged from $1.42 to $2.31, highlighting modest volatility as indicated by an annualized volatility of 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.17 | $1.79 | $2.21 | 0% | Neutral | |
| $1.43 | $1.81 | $2.43 | +1% | Neutral | |
| $1.52 | $1.98 | $2.77 | +10% | Neutral | |
| $1.81 | $2.42 | $3.49 | +35% | Bullish | |
| $1.88 | $2.58 | $3.81 | +44% | Bullish | |
| $1.81 | $2.53 | $3.82 | +41% | Bullish | |
| $1.94 | $2.76 | $4.26 | +54% | Bullish | |
| $1.83 | $2.65 | $4.17 | +48% | Bullish | |
| $1.79 | $2.64 | $4.22 | +47% | Bullish | |
| $2.25 | $3.37 | $5.47 | +88% | Bullish | |
| $2.50 | $4.05 | $7.01 | +126% | Bullish | |
| $4.37 | $8.04 | $15.33 | +349% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.17 | $1.79 | $2.16 | +0.00% |
| August 2026 | $1.57 | $1.86 | $2.26 | +3.56% |
| September 2026 | $1.53 | $1.82 | $2.24 | -2.01% |
| October 2026 | $1.45 | $1.74 | $2.16 | -4.53% |
| November 2026 | $1.44 | $1.74 | $2.18 | +0.01% |
| December 2026 | $1.44 | $1.75 | $2.21 | +0.51% |
Click any year to see its month-by-month IPHA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IPHA price prediction for 2026 points to an average of $1.79 (low $1.17, high $2.21) — a potential gain of 0% on today's $1.79. A consolidation phase looks the most probable path here.
In 2027, IPHA is projected to trade between $1.43 and $2.43, averaging $1.81 — a potential gain of +1% from today's $1.79. That is up +1% on the projected 2026 average. Price action looks broadly range-bound.
Innate Pharma S.A.'s 2028 outlook centres on $1.98, within a $1.52 to $2.77 range. That is up +9% on the projected 2027 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, IPHA could reach as high as $3.49, with a base case around $2.42 and support toward $1.81 — roughly +35% from $1.79. Momentum favours further upside here.
Expect IPHA to range from $1.88 to $3.81 through 2030. The $2.58 average target implies a +44% move from current prices. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The IPHA price prediction for 2031 points to an average of $2.53 (low $1.81, high $3.82) — a potential gain of +41% on today's $1.79. Momentum favours further upside here.
In 2032, IPHA is projected to trade between $1.94 and $4.26, averaging $2.76 — a potential gain of +54% from today's $1.79. That is up +9% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Innate Pharma S.A.'s 2033 outlook centres on $2.65, within a $1.83 to $4.17 range. That is -4% versus the projected 2032 average. That marks a +48% change versus current levels. Momentum favours further upside here.
By 2034, IPHA could reach as high as $4.22, with a base case around $2.64 and support toward $1.79 — roughly +47% from $1.79. Buyers look set to stay in control over this stretch.
Expect IPHA to range from $2.25 to $5.47 through 2035. The $3.37 average target implies a +88% move from current prices. That is up +28% on the projected 2034 average. Momentum favours further upside here.
The IPHA price prediction for 2040 points to an average of $4.05 (low $2.50, high $7.01) — a potential gain of +126% on today's $1.79. Buyers look set to stay in control over this stretch.
In 2050, IPHA is projected to trade between $4.37 and $15.33, averaging $8.04 — a potential gain of +349% from today's $1.79. That is up +99% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IPHA today (≈ 557.880056 IPHA) could be worth
$4,487.97
+$3,487.97 (+349%) by 2050 · US Dollar
Based on the average projected IPHA price of $8.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IPHAwould be worth at today's price.
$1,000 invested in IPHA on Jul 10, 2025 (≈ 552.486205 IPHA) would be worth
$990.33
-$9.67 (-1.0%) today · 0.99× · US Dollar
Based on a IPHA entry price of $1.81 vs. today's $1.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.8 | $995.83 | -0.4% |
| 1 month ago | $1.75 | $1,024.29 | +2.4% |
| 3 months ago | $1.41 | $1,271.28 | +27.1% |
| 6 months ago | $1.82 | $984.89 | -1.5% |
| 1 year ago | $1.81 | $990.33 | -1.0% |
| All time (5.0y) ago | $3.25 | $551.54 | -44.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IPHA forecast.
Our base-case forecast reaches $3.60 around 2040.
Implied market cap at $3.60: $338.05M
The multi-year forecast shows steadily evolving upside, with the 2026 average at $1.81 and 0% ROI, followed by a gradual rise in subsequent years. Notable milestones include 2028 with an average of $2.02 and 11.8% ROI, 2029 with $2.40 and 32.4% ROI, 2030 with $2.59 and 43.1% ROI, and 2035 with $3.31 and 83.1% ROI. The forecast then projects stronger upside in 2040 (average $3.96, ROI 118.9%) and 2050 (average $7.66, ROI 323.3%).
The sentiment remains bullish from 2029 onward, though these are estimates and not guarantees, subject to market conditions and other factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.59 with an ROI of 43.1%, and a bullish sentiment.
Near-term forecasts show a neutral stance (e.g., 2026 with avg $1.81 and ROI 0, 2027 with ROI -2.2), while several later years project bullish growth (e.g., 2029–2050). These are estimates, not guarantees.
The forecast maximum for 2035 is $5.78, suggesting that reaching $5.00 could occur within the horizon of the provided projections.
The current price is $1.81.
The market capitalization is $169.96M.
Innate Pharma S.A. Community Discussion
0Share your Innate Pharma S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.